

Biophytis completes a € 7,5 M capital increase to help accelerate pipeline programs in orphan pediatric diseases

Paris (France), November 1st, 2017, 7:30am – BIOPHYTIS (Euronext Growth Paris: ALBPS), a biotechnology company focused on innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs, announces entry into definitive agreements for a € 7,5 million capital raise via the issuance of new ordinary shares without shareholders' preferential subscription right.

Stanislas Veillet, Chairman and Chief Executive Officer of Biophytis, said: *"We are pleased to announce that we successfully receive commitment for a capital raise to finance the design of a phase 2 clinical program in orphan indications which offer a clear regulatory path and accelerated timelines to market. With the preclinical proofs of concept established for our lead compounds : Sarconeos in Duchenne Muscular Dystrophy, and Macuneos in Stargardt disease, we are at the cusp of adding a new, important pillar addressing pediatric orphan diseases to our advanced pipeline."*

Since July 1st, the Company has raised a total amount of € 21 M that will, besides, allow to conduct the clinical studies of Sarconeos in Sarcopenia (SARA-INT) and Macuneos in AMD (MACA-PK), until their completion.

Invest Corporate Finance acted as global coordinator for the operation. Invest Securities and H.C. Wainwright & Co. acted as exclusive placement agent for the offering in Europe and the United States, respectively.

INVEST
CORPORATE
FINANCE

INVEST
SECURITIES

 HCW
H.C.WAINWRIGHT&CO.

The capital raise by means of a private placement consists in the issuance of 1, 513,000 new ordinary shares at a price of €5.00 per share, representing a discount of 18% based on the weighted average price over the last 10 trading days before pricing. The total amount of the operation is 7,565,000 euros, representing 13% of the share capital of the Company. The new ordinary shares will be the subject of a request for admission to trading on the Euronext Growth market to Euronext.

The Company's Board of Directors approved this capital increase at its meeting of October 31, 2017.

The capital will be increased via the issuance of new shares without shareholders' preferential subscription rights, pursuant to Article 225-138 of the French Commercial Code (reserved to categories of investors). Pursuant to Article 211-3 of the AMF's general regulations, this offer of financial securities did not result in a prospectus subject to AMF approval. The offering is expected to close on or about November 3, 2017.

About BIOPHYTIS:

Biophytis SA (www.biophytis.com), founded in 2006, develops drug candidates targeting diseases of aging. Using its technology and know-how, Biophytis has begun clinical development of innovative therapeutics to restore the muscular and visual functions in diseases with significant unmet medical needs. Specifically, the company is advancing two lead products into mid-stage clinical testing this year: Sarconeos (BIO101) to treat sarcopenic obesity and Macuneos (BIO201) to treat dry age-related macular degeneration (AMD).

The business model of BIOPHYTIS is to ensure the conduct of the project until clinical activity in the patient is proven, then to license the technologies in order to continue the development in partnership with a pharmaceutical laboratory.

The company was founded in partnership with researchers at the UPMC (Pierre and Marie Curie University) and also collaborates with scientists at the Institute of Myology, and the Vision Institute.

BIOPHYTIS is listed on the Euronext Growth market of Euronext Paris (ALBPS; ISIN: FR0012816825).

For more information: <http://www.biophytis.com>



Follow us on Twitter @biophytis

BIOPHYTIS is eligible for the SMEs scheme



Disclaimer

This press release contains certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Listing Prospectus upon the admission of Company's shares for trading on the regulated market Euronext Growth of Euronext Paris filed with the AMF, which is available on the AMF website (www.amf-france.org) or on BIOPHYTIS' website (www.biophytis.com).

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in BIOPHYTIS in any country. Items in this press release may contain forward-looking statements involving risks and uncertainties. The Company's actual results could differ substantially from those anticipated in these statements owing to various risk factors which are described in the Company's prospectus. This press release has been prepared in both French and English. In the event of any differences between the two texts, the French language version shall prevail.

BIOPHYTIS

Stanislas VEILLET

CEO

contact@biophytis.com

Tel: +33 (0) 1 41 83 66 00

Citigate Dewe Rogerson

Presse internationale & Investisseurs

Laurence BAULT/Antoine DENRY

Laurence.bault@citigate.fr

antoine.denry@citigate.fr

Tel: +33 (0)1 53 32 84 78

Mob: +33(0)6 64 12 53 61

LifeSci Advisors

Chris MAGGOS

Managing Director, Europe

chris@lifesciadvisors.com

Tel: +41 79 367 6254